A TP-sensitive potassium (K ATP ) channels are heterooctamers found in multiple cell types. 1 The channel is composed of a pore-forming unit, Kir6.x, and a regulatory subunit, the sulfonylurea receptor (SUR). K ATP channels are sensitive to intracellular energetic changes and are inhibited by ATP and stimulated by MgADP. 2 The electrophysiological and pharmacological properties of K ATP channels vary from tissue to tissue depending on the expression pattern of the specific Kir6.x and SUR subunits that constitute the channel. Biophysical profiles of K ATP channels in native cells and tissues have been compared with heterologously expressed Kir6.x and SUR subunits to understand the composition of K ATP channels in different tissues. For example, heterologous expression of Kir6.2 and SUR1 generates channels with a signature that closely matches the characteristics of native pancreatic ␤-cell and neuronal K ATP channels.
In the cardiovascular system, Kir6.2 and SUR2 constitute the major K ATP channels of the heart reflecting expression in cardiomyocytes. 1 SUR2 undergoes alternative splicing, 3, 4 where either exon 39 or exon 40 encodes the cytoplasmic carboxy terminus. SUR2 with exon 39 (SUR2A, also known as SUR2 (39) ) is found in cardiomyocytes and skeletal myofibers. 5 In cardiomyocytes, K ATP channels are quiescent at baseline and are activated by hypoxic or ischemic insults. The resultant potassium flux leads to a shortening of the action potential duration and cellular protection. 6 -8 In addition to this role, K ATP channels have been implicated in ischemic preconditioning, 9 -12 the process where short bouts of ischemia before an index ischemic event activates intracellular signals and a transcriptional gene program that confers cellular protection. K ATP channels are also involved in the normal cardiac response to adrenergic stress. 13 In smooth muscle, including vascular smooth muscle, an alternatively spliced form of SUR2 that contains exon 40 (SUR2B, also known as SUR2 (40)) is present. SUR2A and SUR2B differ in the carboxy-terminal 42 amino acids. Heterologous expression of SURB along with Kir6.1 results in a small-conductance, glibenclamide-sensitive potassium channel that is relatively insensitive to ATP, resembling the channel found in native vascular smooth muscle cells. 14 These channels have been implicated in the regulation of resting coronary tone. Vascular K ATP channels have also been implicated in the coronary vasodilatory response to exercise 15 and hypoxia. 16 K ATP channels may also play a role in endotoxic vasodilation. 17 Independent gene targeting studies in mice of either the gene encoding SUR2 (ABCC9) or Kir6.1 (KCNJ8) produced an identical phenotype of coronary artery spasm seen as transient ST segment elevation accompanied by atrioventricular heart block, bradycardia, and sudden death. 18, 19 As these genetically modified mice carried gene deletions that affected gene expression in all tissues, the origin of vascular spasm in Kir6.1 and SUR2 null mice was believed to result from of a loss of coronary artery vascular smooth muscle K ATP channels, the common and overlapping cell type affected by both gene targeted mutants. To test the hypothesis that coronary artery smooth muscle K ATP channels are responsible for the coronary artery spasm and sudden death seen in Kir6.1 and SUR2 null mice, we used the SM22␣ promoter to express SUR2B in SUR2 Ϫ/Ϫ mice. Despite expression and reconstitution of vascular K ATP channels, the phenotype of ST segment elevation and coronary artery vasospasm persisted, consistent with a vascular smooth muscle cell extrinsic mechanism of vascular spasm.
Materials and Methods

Transgenic Construct
The 2B isoform of SUR2 (SUR2B) was amplified from a mouse heart cDNA library and placed between the terminal 441 base pairs (bp) of the SM22␣ promoter 20 and the bovine growth hormone termination and polyadenylation signal sequence. The plasmid (SM22-SUR2B) was verified by sequencing, digested, separated from the plasmid backbone, and purified before injection into fertilized oocytes.
Animals
SUR2
Ϫ/Ϫ mice were described previously. 19, 21 The SUR2 mutant allele was bred heterozygously into the FVB background. The SM22-SUR2B transgene was injected into fertilized oocyte pronuclei generated from a cross between SUR2 Ϫ/Ϫ females and FVB wild-type males (The Jackson Laboratory, Bar Harbor, Me). Transgene copy number was assessed by quantitative PCR using genomic DNA conducted in triplicate using transgene-specific primers with fold changes normalized to the apolipoprotein B reverse-transcribed transcript. Two transgene-positive SUR2 ϩ/Ϫ founders were selected and independently mated to SUR2 Ϫ/Ϫ and SUR2 ϩ/ϩ mice. Animals were housed, treated, and handled in accordance with the guidelines set forth by the University of Chicago's Institutional Animal Care and Use Committee, the Animal Welfare Act regulations, and the NIH Guide for the Care and Use of Laboratory Animals. All comparisons were made to littermates. All studies were performed on male mice between 8 and 12 weeks of age unless otherwise noted.
Reverse-Transcription PCR
Total RNA was extracted from homogenized descending aortae using TRIzol reagent according to the protocol of the manufacturer (Invitrogen, Carlsbad, Calif). RNA pellets were resuspended in diethylpyrocarbonate-treated water and DNase treated (Turbo DNAfree, Ambion, Austin, Tex). Complementary DNA was synthesized using Superscript III reverse transcriptase (Invitrogen). Transgene-specific primers were used to detect products from the SM22-SUR2B transgene (SM22␣ promoter forward: 5Ј AGACAC-CGAAGCTACTCTCC 3Ј, SUR2 exon 4 reverse: 5Ј GCGGAAG-GCATCGTTTCAGA 3Ј; SUR2 exon 38 forward: 5Ј AGTCATGA-CAGCCTTTGCGG 3Ј, BGH terminator reverse: 5Ј GCCTTCTA-GTTGCCAGCCAT 3Ј).
Cell Isolation and Electrophysiology
Aortic smooth muscle cells were isolated as previously described. 22 Purity of the isolation for smooth muscle was ascertained on a subset of cells by immunofluorescence staining with an anti-smooth muscle ␣-actin antibody (Sigma-Aldrich, St Louis, Mo), and cell viability was ascertained by Trypan blue dye exclusion (Sigma-Aldrich). Only cells displaying the typical spindle-shape of smooth muscle by phase-contrast microscopy were used in patch-clamp experiments.
Conventional patch-clamp whole cell recording was performed at 20°C to 22°C. 23 To ensure the opening of 2 types of K ATP channels reported in smooth muscle cell, 3, 14 ATP was omitted and Mg 2ϩ and UDP included in the pipette. The whole cell current was generated by clamp pulses from a holding potential of Ϫ70 mV to voltages ranging from Ϫ120 to 20 mV in 20-mV steps for 260 ms. The currents were filtered at 1 kHz and sampled at 5 kHz. Data were digitally stored for off-line analysis using the pClamp software. Whole cell currents usually reached maximal levels 2 minutes after membrane rupture. Extracellular application of pinacidil 200 mol/L (Parke Davis, Ann Arbor, Mich) could not further increase the current amplitude. The whole cell current could be partially blocked by 20 mol/L glibenclamide (Sigma-Aldrich). The glibenclamidesensitive current was interpreted as K ATP current 19 and was normalized by cell capacitance to obtain the whole cell current density. PCR was conducted using primers specific to the SM22-SUR2B transgene spanning from SUR2 exon 38 into the termination sequence to yield the expected product of 211 bp.
Antibodies
An anti-SUR2 antibody, BNJ-2, was raised in rabbits. The peptide sequence QSKPINRKQPGRYH was conjugated to KLH before use as an antigen. This sequence falls within nucleotide binding fold 1. BNJ-2 was affinity purified using the antigenic peptide. The specificity of this antibody was determined by heterologous expression (data not shown). The monoclonal anti-smooth muscle ␣-actin antibody was from Sigma-Aldrich (catalog number A5228). Secondary antibodies included goat anti-mouse Alexa488 and goat antirabbit Alexa596 (Invitrogen). Primary antibodies were diluted to 1:8000 and 1:300 for BNJ-2 and the anti-smooth muscle ␣-actin, respectively. Secondary antibodies were diluted to 1:2000 and 1:6000 for Alexa488 and Alexa596, respectively.
Immunofluorescence Microscopy
Hearts were frozen in liquid nitrogen-cooled isopentane, sectioned at a thickness of 8 m and fixed in Ϫ20°C methanol for 10 minutes. Hearts were sectioned from base to apex and a minimum of every tenth section was examined for the presence of arteries using the anti-smooth muscle ␣-actin antibody to confirm the presence of arteries. Fluorescent images were viewed and captured using the Axioskop, AxioCam, and AxioVision microscope, camera, and software systems (Carl Zeiss Inc, Oberkochen, Germany).
Ambulatory Electrocardiographic Recordings
Continuous ambulatory electrocardiographic (ECG) recordings were obtained as described previously. 19 Recording was begun after a 24-hour recovery period for 48 hours. ECG tracings were manually analyzed for spontaneous ST segment changes. ST segment frequency and duration during the first 2 hours of recording were quantified by an investigator blinded to mouse genotype. Heart rate variability was calculated as the SD of the mean R-R intervals over the recording period.
Microvascular Filling
Coronary artery microvascular filling was performed as described previously. 19 Hearts were examined blinded to age, genotype, and animal number. Vessels found to be filled with Microfil were scored for presence or absence of focal narrowings, representing areas of focal vasospasm.
Coronary Perfusion Pressure
Mice were heparinized (0.5 U/g body weight) and anesthetized (inhaled 3% isoflurane). The hearts were then rapidly excised and transfused via a 24-gauge cannula (Fine Science Tools, Foster City, Calif) placed immediately distal of the intact aortic valve. Hearts were perfused at constant flow (Ϸ4.5 mL/min) with Krebs-Henseleit solution (in mmol/L: 120 NaCl, 4.7 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 15 glucose, 25 NaHCO 3 , 1.75 CaCl 2 , 0.05 EDTA) equilibrated with 95% O 2 and 5% CO 2 at 37°C using a standard Langendorff setup (Radnoti Glass Technology, Monrovia, Calif). Coronary perfusion pressure was continuously recorded using a pressure-sensing catheter (Millar Instruments, Houston, Tex) connected to the perfusion cannula. Hearts were equilibrated for at least 20 minutes before exposure to methylergonovine (10 mol/L, Sigma-Aldrich, catalog no. M2776) for 20 minutes. Hearts were maintained at 37°C via a water-jacketed tissue-organ bath for the duration of the experiment (Nϭ3 in each group).
Statistical Analysis
All quantified results are reported as meanϮSD unless otherwise noted. A Student's t test was used to compare means where appropriate. A 
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cutoff probability value of 0.05 was used unless otherwise noted. For coronary perfusion pressure measurements, a 1-way ANOVA followed by Newman-Keuls multiple comparison tests was used.
Results
Smooth Muscle Restricted Expression of SUR2B
We generated mice carrying a transgene to drive expression of SUR2B, the dominant isoform found in vascular smooth muscle, in coronary arteries using the SM22␣ promoter and following a strategy we had used previously ( Figure 1A ). 24 The terminal 3Ј end of the SM22␣ promoter has been shown to be necessary and sufficient to drive expression specifically in arterial smooth muscle cells 20, 25 from mid-embryogenesis through adulthood. 26 Mice harboring the SM22-SUR2B transgene were subsequently bred to mice with the null allele of SUR2 to produce mice with restoration of coronary artery vascular smooth muscle K ATP channels. Two independent SM22-SUR2B transgenic lines were generated and examined. Line 8 had a copy number of 3, and line 14 had a copy number of 12. Founder mice and their progeny were viable and fertile. The presence of mRNA produced from the SM22-SUR2B transgene was determined by RT-PCR of total RNA prepared from aortae ( Figure 1B) . Protein expression from the SM22-SUR2B transgene was documented by immunostaining using a rabbit polyclonal antibody raised against a region of the first nucleotide binding fold of SUR2 (Figure 2) . Specificity of this BNJ-2 antibody was shown by its reactivity to normal coronary arteries and cardiomyocytes and its lack of reactivity to coronary arteries and cardiomyocytes in SUR2 null hearts (Figure 2 ). SUR2 immunoreactivity was seen consistently in both large and small vessels throughout the heart. Costaining with an antismooth muscle ␣-actin antibody was used to document the identity of coronary arteries and consistently appeared with SUR2 immunoreactivity as shown in Figure 2 .
Restoration of Vascular Smooth Muscle K ATP Channel Activity
Transgene-driven K ATP channel activity was documented using whole cell patch clamp of isolated aortic vascular smooth muscle cells from SUR2 null mice with and without the SM22-SUR2B transgene. Cells isolated from both transgenic lines exhibited pinacidil-evocable, glibenclamidesensitive currents, consistent with the known pharmacological characteristics of native K ATP channels ( Figure 3A ). Whole cell current density in both lines was not statistically different from wild type ( Figure 3B) , consistent with the generation of the appropriate channel density within arterial smooth muscle.
Coronary Artery K ATP Channel Activity Fails to Correct Coronary Artery Vascular Spasm
We examined SUR2 null mice with and without the SM22-SUR2B transgene for the presence of coronary artery vascular spasm using radiofrequency ambulatory monitoring. SUR2 null mice display frequent and repeated episodes of transient ST segment elevation that frequently associate with atrioventricular heart block and occasionally bradycardia, agonal rhythms, and death. Surprisingly, transgene-restored SM22-SUR2B/SUR2 null mice also displayed frequent, transient ST segment elevation indistinguishable from that seen in SUR2 null mice (Figure 4) . After 48 hours of ambulatory ECG recording, SM22-SUR2B/SUR2 Ϫ/Ϫ mice were compared with their SUR2 Ϫ/Ϫ littermate controls. No statistically significant difference in mean heart rate ( Figure 5A ) or heart rate variability ( Figure 5B ) was seen between the groups. In mice surviving through the recording period, mean PR and QRS interval duration were not different between SM22-SUR2B/SUR2 Ϫ/Ϫ mice and their SUR2 Ϫ/Ϫ littermate controls (data not shown). Quantitation of these episodes revealed no statistically significant difference in the amount and duration of ST segment elevation between SM22-SUR2B/SUR2 Ϫ/Ϫ mice and SUR2 null mice ( Figure 5C ). We also examined whether the presence of the transgene alone, in a wild-type background, was sufficient to produce ST segment elevation. We monitored the heart rates of animals from line 8 and found no evidence of ST segment elevation or other ECG abnormalities.
Evidence of Persistent Coronary Vasospasm in Transgenic Mice
A microvascular filling technique was used to demonstrate arterial narrowing consistent with vascular spasm in SUR2 null mice. 24 Because ECG evidence of vasospasm was documented in both lines of SM22-SUR2B/SUR2 null mice, we used this microvascular filling technique to examine transgene-restored mice for the presence of coronary artery vascular spasm. Microvascular evidence for coronary spasm was documented in both transgene-restored lines as well ( Figure 6A ).
We also examined coronary perfusion pressure in littermate control as well as SUR2 null mice with and without the SM22-SUR2B transgene. The mean baseline coronary perfusion pressure in control mice (nϭ3) was 69Ϯ5 mm Hg. Ϫ/Ϫ transgene-negative mouse. Frequent episodes of transient, spontaneous ST segment elevation, usually followed by ST segment depression and atrioventricular heart block were noted in SUR2 Ϫ/Ϫ mice as previously reported. 24 Row 3 shows a representative ECG tracing from an SM22-SUR2B/ SUR2
Ϫ/Ϫ transgene-positive mouse. Similar to SUR2
Ϫ/Ϫ mice, episodes of ST segment elevation, depression and heart block were seen in transgene-positive SUR2 Ϫ/Ϫ mice. B, Infrequently, the persistent bradycardia would progress to agonal rhythms and death. Representative tracings corresponding to the numbers shown along the graph in B are shown in to the right in C. C, Tracing corresponding to the graph in B. 1ϭnor-mal sinus rhythm; 2ϭST segment elevation followed by ST segment depression; 3ϭ2:1 atrioventricular block; 4ϭcontin-ued AV block with wide QRS interval.
SUR2 null mice with and without the SM22-SUR2B transgene exhibited elevated baseline coronary perfusion pressures of 111Ϯ3 and 115Ϯ7 mm Hg, respectively, significantly higher than control mice ( Figure 6B ). Methylergonovine treatment (10 mol/L) of control mice induced a mild, insignificant increase in coronary perfusion pressure to 79Ϯ2 mm Hg. In contrast, methylergonovine produced sta- Figure 5 . Heart rate, heart rate variability, and ST segment duration and frequency in transgene restored mice. A, Mean heart rate was calculated from ECG recordings of SUR2 null and SUR2 null mice in the presence of the SM22-SUR2B transgene (Tg ϩ ). No significant difference in mean heart rate was seen. Similarly, no significant differences were seen between transgene-positive and transgene-negative control (SUR2 ϩ/ϩ ) mice (nϭ5 mice per group). B, Heart rate variability was calculated from the ECG recordings in A. Variability was calculated as the SD of the mean R-R interval (SDNN) measured over the 48-hour recording period. No significant differences in heart rate variability were seen between SUR2 null mice and SUR2 null mice in the presence of the SM22-SUR2B transgene (Tg ϩ ), (nϭ5 mice per group). Similarly, no significant differences were seen between transgene positive and transgene negative control (SUR2 ϩ/ϩ ) mice. C, Episodes of ST segment elevation were compared between SUR2 null mice and SUR2 null mice with the SM22-SUR2B transgene (Tg Ϫ and Tg ϩ , respectively). The total duration of ST segment elevation during the first 2 hours of ECG recording was measured and the average taken (nϭ5 mice per group). There was no significant difference in the frequency and duration of ST segment elevation between the 2 groups. Ϫ/Ϫ mice from both independent SM22-SUR2B transgenic lines display evidence of coronary spasm. Scale barϭ100 mol/L. B, Coronary perfusion pressures were measured in isolated working hearts from control, SUR2 null, and transgene-restored mice. SUR2 null mice display elevated baseline coronary artery perfusion pressures. Infusion of methylergonovine resulted in a further increase in coronary perfusion pressure, whereas a similar infusion in control mice produced an increase that was not statistically significant. SM22-SUR2B hearts showed a similar increase in baseline coronary artery perfusion pressure that was statistically significant from control but not from SUR2 null mice. Similarly, infusion of methylergonovine produced an increase in coronary artery vascular pressure consistent with enhanced spasm that was not seen in wild-type control mice. *PϽ0.05, nϭ3 in each group. All other comparisons were not statistically significant. tistically significant increases of coronary perfusion pressure in SUR2 null mice with and without the SM22-SUR2B transgene (137Ϯ5 and 147Ϯ13 mm Hg, respectively). These data directly demonstrate that coronary artery perfusion pressure at baseline and in response to methylergonovine remained functionally abnormal despite restoration of arterial vascular SUR2-K ATP channels.
Discussion
Here we show a persistent phenotype of coronary artery vascular spasm in mice engineered to lack SUR2 despite restoration of vascular smooth muscle K ATP channels. Smooth muscle restoration of coronary artery K ATP channels was ineffective in reducing spasm and the consequent atrioventricular heart block and sudden death that accompanies this spasm. These findings indicated that coronary artery vascular spasm associated with global loss of SUR2-Kir6.1 K ATP channels arises from a vascular smooth muscle cell-extrinsic process. Although never directly tested, the etiology of vasospasm in mice with targeted gene deletions of Kir6.1 or SUR2 had been attributed to the loss of K ATP channels in smooth muscle. 18, 19 The presumed role of the vascular smooth muscle etiology was surmised based on the overlapping patterns of expression of these genes; both Kir6.1 and SUR2 are found in vascular smooth muscle. Considerable evidence suggests that the smooth muscle K ATP channel is composed of Kir6.1 and SUR2B. 3, 14 However, it should be noted that both subunits are coexpressed in other cell types such as endothelial [27] [28] [29] and neuronal cell types. 30 -33 Although not the dominant K ATP channel, low-level expression is also present in cardiomyocytes. 18, 28, 34 Mice lacking SUR2 do not show the normal vascular reactivity to glibenclamide and pinacidil, supporting a role for SUR2-K ATP channels in the regulation of vascular tone. 19 Our current studies have focused on expression of SUR2 in coronary artery vascular smooth muscle and in aortic smooth muscle because the SM22 promoter drives expression in these tissues. However, despite functional expression in these tissues, evidence for coronary artery spasm and increased coronary artery perfusion pressure remained. There is evidence to support a role for endothelial K ATP channels in vascular function and, potentially, in the regulation of vascular tone and vascular spasm. Adenosine 35 and ␣2-adrenergic 36 vasodilatation may be dependent on endothelial K ATP channels. However, in the rat aorta, vasodilation induced by opening of K ATP channels was not affected by endothelial denudation, indicating that other mechanisms may be sufficient to override endothelial control.
Neuronal K ATP channels may also contribute to vasospasm and sudden death seen in SUR2 null mice. The ability of the autonomic nervous system to induce coronary spasm has been documented, 37, 38 and a role for autonomic hyperactivity in human variant angina has been postulated. 39 Blockade of K ATP channels was shown to augment the normal increase in coronary vascular resistance seen with sympathetic nerve stimulation. 40 This effect may be mediated by an unopposed neuropeptide Y effect. 41 More recently, it has been proposed that the attenuation of cardiac norepinephrine overflow seen during low-flow ischemia may be mediated in part by the opening of presynaptic K ATP channels. 42 In skeletal muscle, the normal contraction-induced attenuation of sympathetic vasoconstriction is partially abolished by inhibition of K ATP channels. 43 These studies point to a possible role of the pre-synaptic K ATP channel of sympathetic neurons in the etiology of coronary spasm.
Our studies demonstrate that spontaneous coronary artery vasospasm seen in mice lacking SUR2 arises from a vascular smooth muscle-extrinsic process. This surprising finding suggests that the loss of K ATP channels in an organ system in close interaction with the coronary vasculature is vital for normal coronary function as studies in isolated hearts showed evidence of abnormal vascular reactivity, eliminating more distant regulators of vascular tone. A precedent for the involvement of K ATP channels in tissue and organ system crosstalk has recently been noted in the central nervous system. Hypothalamic K ATP channel function affects systemic glucose homeostasis indirectly by altering pancreatic ␣-cell glucagon secretion 44 and hepatic gluconeogenesis. 33 It is possible that the normal, K ATP -mediated regulation of cardiovascular function may also be controlled though multiorgan system or, more likely, a proximal paracrine effect mediated by the neuronal or endothelial crosstalk to vascular smooth muscle.
